Evaluation of neutrophil-to-lymphocyte ratio prior to prostate biopsy to predict biopsy histology: Results of 1836 patients

Canadian Urological Association Journal

Volumn 9, Issue 11-12, 2015, Pages E761-E765

  Gokce, Mehmet Ilker ^a   Hamidi, Nurullah ^a   Suer, Evren ^a   Tangal, Semih ^b   Huseynov, Adil ^a   Ibiş, Arif ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b UFUK UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGE DISTRIBUTION; AGED; ARTICLE; CONTROLLED STUDY; GLEASON SCORE; HISTOLOGY; HUMAN; HUMAN TISSUE; LYMPHOCYTE COUNT; MALE; NEUTROPHIL COUNT; NEUTROPHIL LYMPHOCYTE RATIO; PREDICTIVE VALUE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATITIS; TRANSRECTAL ULTRASONOGRAPHY;

EID: 84946569747     PISSN: 19116470     EISSN: 19201214     Source Type: Journal    
DOI: 10.5489/cuaj.3091     Document Type: Article

References (19)

1. Boyle P, Ferlay J. Cancer incidence and mortality in Europe 2004. Ann Oncol 2005;16:481-8. http://dx.doi.org/10.1093/annonc/mdi098
2. Arnold M, Karim-Kos HE, Coebergh JW, et al. Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory. Eur J Cancer 2015;51:1164-87. http://dx.doi.org/10.1016/j.ejca.2013.09.002
3. Rosario DJ, Lane JA, Metcalfe C, et al. Short term outcomes of prostate biopsy in men tested for cancer by PSA: A prospective evaluation within the ProtecT study. BMJ 2012;344:d7894. http://dx.doi.org/10.1136/bmj.d7894
4. Casamassima A, Picciariello M, Quaranta M, et al. C-reactive protein: A biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. J Urol2005;173:52-5. http://dx.doi.org/10.1097/01.ju.0000146713.50673.e5
5. Ohno Y, Nakashima J, Ohori M, et al. Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma. J Urol 2010;184:873-8.http://dx.doi.org/10.1016/j.juro.2010.05.028
6. Langsenlehner T, Thurner EM, Krenn-Pilko S, et al. Validation of the neutrophil-to-lymphocyte ratio as a prognostic factor in a cohort of European prostate cancer patients. World J Urol 2015;1-7; Epub 24January 2015; http://dx.doi.org/10.1007/s00345-015-1494-7
7. Nuhn P, Vaghasia AM, Goyal J, et al. Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel. BJU Int 2014;114:E11-7. http://dx.doi.org/10.1111/bju.12531
8. Atzpodien J, Royston P, Wandert T, et al. Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer 2003;88:348-53. http://dx.doi.org/10.1038/sj.bjc.6600768
9. Fumagalli LA, Vinke J, Hoff W, et al. Lymphocyte counts independently predict overall survival in advanced cancer patients: A biomarker for IL-2 immunotherapy. J Immunother 2003;26:394-402. http://dx.doi.org/10.1097/00002371-200309000-00002
10. De Marzo AM, Platz EA, Sutcliffe S, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007;7:256-69. http://dx.doi.org/10.1038/nrc2090
11. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7. http://dx.doi.org/10.1038/nature01322
12. Heikkila K, Ebrahim S, Lawlor DA. A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health 2007;61:824-33. http://dx.doi.org/10.1136/jech.2006.051292
13. dos Santos Silva I, De Stavola BL, Pizzi C, et al. Circulating levels of coagulation and inflammation markers and cancer risks: Individual participant analysis of data from three long-term cohorts. Int J Epidemiol 2010;39:699-709. http://dx.doi.org/10.1093/ije/dyq012
14. Guthrie GJK, Charles KA, Roxburgh CSD, et al. The systemic inflammation-based neutrophil - lymphocyte ratio: Experience in patients with cancer. Crit Rev Oncol Hematol 2013;88:218-30. http://dx.doi.org/10.1016/j.critrevonc.2013.03.010
15. Roxburgh CSD, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 2009;6:149-63. http://dx.doi.org/10.2217/fon.09.136
16. Beer TM, Lalani AS, Lee S, et al. ASCENT Investigators. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: Results from the ASCENT trial. Cancer 2008;112:2377-83. http://dx.doi.org/10.1002/cncr.23461
17. Hamidi N, Gökçe MI, Süer E, et al. Evaluation of increased preoperative serum high sensitive C-reactive protein and procalcitonin levels on grade and stage of clear cell renal cell carcinoma. Clin Nephrol 2015;83:225-30. http://dx.doi.org/10.5414/cn108448
18. McDonald AC, Vira MA, Vidal AC, et al. Association between systemic inflammatory markers and serum prostate-specific antigen in men without prostatic disease - the 2001-2008 National Health and Nutrition Examination Survey. Prostate 2014;74:561-7. http://dx.doi.org/10.1002/pros.22782
19. Fujita K, Imamura R, Tanigawa G, et al. Low serum neutrophil count predicts a positive prostate biopsy. Prostate Cancer Prostatic Dis 2012;15:386-90. http://dx.doi.org/10.1038/pcan.2012.27